DIAGNOSTICS

Phenomix Sciences Announces First Obesity Biobanking Registry and Outcomes Study for Precision Nutrition and Obesity

Phenomix Sciences | May 27, 2022

Pheno_mix_Sciences
Phenomix Sciences (Phenomix), a precision biotechnology company bringing data intelligence to the treatment of obesity, announces today the launch of its biobanking registry and outcome study. The registry will study variability in obesity by looking at patients' DNA, metabolomics, hormones, patient behavior, assessments, and treatment outcomes. The data collected will supplement the 20 billion unique data points that make up the Phenomix Sciences Obesity Platform. Mayo Clinic is the first to enroll in the registry with its Rochester site set to contribute patient outcomes from 2,000 patients undergoing treatment for obesity to its biobank. 

The biobanking registry is a critical milestone in Phenomix's mission to conquer obesity by creating unprecedented access to its clinical and molecular information throughout all stages and phenotypes of the disease.  Outcomes data generated from the biobanks across the registry will supplement Phenomix's database of biological and clinical data matched to the four obesity phenotypes.  Insights generated from the database are being used to develop more predictive tests to identify the right intervention for each patient with obesity.  This will allow for a better understanding of variability in patient outcomes when undergoing obesity treatments. Despite the justifiable excitement about new weight management products such as semaglutide and tirzepatide, several clinical studies from Phenomix's founders indicate that patient response varies with underlying phenotype. Thus, for many patients, it will open the door to the most effective and appropriate intervention for their unique phenotype.

A growing body of evidence indicates that obesity is not a single disease with a single treatment type, but a constellation of diseases. Obesity's roots lie in individual DNA; however, evidence suggests there is a complicated web connecting obesity to age, race, and gender, education, and socioeconomic status. Understanding a person's obesity phenotype — the combination of genes with environmental and behavioral factors — can help pinpoint the cause of weight gain. Phenomix's phenotypes are based on research from its physician founders, Andres Acosta, MD, PhD and Michael Camilleri, MD of Mayo Clinic, that has demonstrated when patients have been phenotyped and prescribed the right medications, they can achieve up to 16 percent total body weight loss (TBWL).

In addition to creating the first biobanking registry of this type, this is the first large scale study to monitor phenotypes in patients with obesity being treated with a variety of treatments. The impact of this biobanking registry and the data it will yield has the potential to change the entire system's approach to obesity, from a treatment recommendation to the way payers determine coverage and how industry combines diagnostics testing with drug therapy.

This unique biobanking registry will provide critical and contemporary data on obesity outcomes, impacting every stakeholder in the episode of care, This registry is an important opportunity to make vast strides in how we understand the complexities of obesity treatment. All obesity programs should be seeking the opportunity to participate and contribute to this registry. The more data we have on the variables that contribute to an individual's obesity diagnosis, the more lives we can save by putting the best treatment plan forward. We believe the investment in the biobanking registry will better support obesity centers by providing concrete evidence and insight into how DNA and other factors need to be considered in treatment. Patients can benefit greatly from achieving the desired outcome the first time around, and payers avoid paying for trial-and-error approaches and can reduce overall co-morbid conditions for members."

Mark Bagnall, CEO of Phenomix Sciences.

About Phenomix Sciences
Phenomix Sciences is a biotechnology pioneer on a mission to conquer obesity globally through the science of phenotyping, the understanding of how genes combined with environmental and behavioral factors can inform obesity treatment plans. Mayo Clinic physicians, scientists, and researchers, Andres Acosta, MD, and Michael Camilleri, MD, founded the company under the belief that the key to understanding obesity is unprecedented access to its clinical and molecular information throughout all stages and phenotypes of the disease.  Phenomix leverages data intelligence for yielding better accuracy in predicting individual patient response to specific weight loss interventions and reducing the variability in weight loss results for patients.

Spotlight

Tuberculosis (TB) is currently a global pandemic. The World Health Organization (WHO) estimates that 2 billion people (a third of the worlds population) is infected with Mycobacterium tuberculosis, the bacterium which causes the disease. Fisher BioServices UK is currently collaborating with partners on a global phase III clinical trial to create a biobank of blood, urine and sputum samples taken from TB-positive patients during treatment.


Other News
MEDICAL

Pharmactive Enters Strategic Partnership with Nutraconnect for APAC

Pharmactive | June 08, 2022

Pharmactive Biotech Products, S.L.U., announces a new strategic partnership with Singapore-based Nutraconnect Pte, Ltd. to bring innovative, scientifically backed nutraceutical ingredients to the Asia-Pacific marketplace (not including Australia and New Zealand). The partnership will combine the strengths of both companies into a greater whole. Pharmactive will provide its well-supported, clean-label botanical extract ingredients, while Nutraconnect will function as a growth engine for the region, connecting Pharmactive with local and regional nutraceutical players seeking high-quality, pure ingredients. Nutraconnect Pte., Ltd. is a start-up led by Rohit Noronha, co-founder and Chief Growth Officer, and Nikhil Prabhakar Sawant, co-founder and CEO. Both are highly experienced leaders in the nutraceutical industry. We are very fortunate to partner with Nutraconnect, as their team possesses a great deal of market and customer information and strategic insight, allowing for quick responses to potential customers in their local time-zone, Asia is a tremendous growth-hub for Pharmactive. We already have had successes in Korea, Japan, Vietnam, and Malaysia with Affron® pure saffron extract and Aged Black Garlic [ABG+®]. Many Asian industry players, formulators, and brand owners approach us about new compounding formats or innovative product concepts to cross the nutraceutical/functional food and beverage divide. Asia is clearly the frontrunner in terms of new ingredient concepts." Jean-Marie Raymond, CEO and Founder of Pharmactive. About Pharmactive Pharmactive Biotech Products, S.L.U., is a Madrid-based pioneering biotechnology company that develops and manufactures differentiated natural ingredients supported by science, such as pure saffron extract and aged black garlic. The company's mission is to make a daily positive and significant impact on people's health and well-being through premium botanical ingredients backed by scientific studies and approved by ethics committees. Pharmactive grows, cultivates, and produces farm-to-fork botanical ingredients with a minimal ecological footprint. About Nutraconnect Founded in 2022, Nutraconnect Pte., Ltd., is a nutraceutical business growth acceleration service headquartered in Singapore. The company provides end-to-end solutions for global nutraceutical ingredient manufacturers that are looking to establish a foundation for sustainable growth in the fragmented, but booming APAC market.

Read More

MEDICAL

Anitoa Launches Molecular Test (PCR) for Monkeypox

Anitoa | June 30, 2022

Anitoa Systems, market leader in fast, portable molecular testing, today announced the availability of a CE-marked turn-key PCR solution for testing Monkeypox. This portable solution includes one of a family small foot-print real time PCR instruments called the Maverick qPCR, with an extraction-free multiplex PCR reagent that tests OPXV/MPXV gene-targets in the skin lesion sample from patients suspected of infection with Monkeypox. Anitoa's Monkeypox test is designed to be carried out on-site, near patient, thus avoiding the need to transport patient samples to central labs for testing. The World Health Organization reported that over 2,100 people in 42 countries have been diagnosed with monkeypox as of June 15, nearly all during the past two months. As of June 17, the CDC reports 24 confirmed monkeypox cases in California, US. Although The CDC reports that the threat to the general U.S. population is considered low, it is important for healthcare providers worldwide to have a preparedness plan. Already having a presence in Africa, Anitoa Systems has started deloying its near-patient Monkeypox test in selected clinics in Africa. Anitoa is prepared to deliver its Monkeypox test solution world-wide when the need arises. Anitoa's Maverick line of multiplex real time PCR devices are lab-accurate, fast, portable and calibration-free. They can operate on battery power (including car battery) and takes up very little bench space. Maverick qPCR instruments are built on Anitoa's proprietary CMOS biosensor technology. They have been used widely for on-site testing of food, environment samples and agriculture products due to its rugged all solid-state design, small form factor, and lower operation cost. Anitoa's Monkeypox detection solution is part of an on-going program at Anitoa to develop tests to help combat a series of neglected tropical diseases in low resource settings. These tests currently include IVDR tests for Dengue, Yellow Fever, and Malaria We are closely monitoring the situation of Monkeypox infections around the world and tailoring our test solutions to the needs of the people affected." Zhimin ding, CEO of Anitoa Systems, LLC About Anitoa Anitoa Systems, a medical device technology start-up established in 2013 with headquarter in Sunnyvale, California, develops highly integrated and portable bio-sensor devices for molecular detection, based on its unique CMOS image sensor-based fluorescence and chemiluminescence molecular imaging. By replacing the traditional bulky and costly photon-multiplier tube (PMT) and CCD-based optical sub-systems, Anitoa's ultra-low-light CMOS sensor technology enables a new generation of compact and inexpensive molecular testing platforms targeting infectious, oncology and cardio-vascular markers. Anitoa manufactures its qPCR instruments and test kits in Hangzhou, China and Fremont, California.

Read More

Cortexyme Successfully Completes Acquisition of Novosteo

Cortexyme | May 21, 2022

Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company developing therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced the completion of its acquisition of Novosteo, a privately-held biotech company focused on targeted therapeutics to treat rare skeletal diseases, bone cancer and injury. Novosteo stockholders now own approximately 15.5% of the combined company. With the completion of the acquisition, Cortexyme appointed former Novosteo executives Dr. Dirk Thye as Chief Executive Officer, and Dr. Karen Smith as Chief Medical Officer of Cortexyme. Dr. Thye and Dr. Philip Low have been appointed to the Cortexyme’s Board of Directors. Cortexyme plans to change its name to Quince Therapeutics, Inc. in the coming months to reflect the broadening pipeline of the company. Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) In conjunction with the close of the Novosteo acquisition, Cortexyme reported that the Compensation Committee of the company’s Board of Directors approved grants of stock options to purchase an aggregate of 3,744,255 shares of Cortexyme’s common stock, which includes options to purchase (i) 1,979,650 shares to Dr. Dirk Thye, (ii) 1,365,449 shares to Dr. Karen Smith, (iii) 353,656 shares to Brendan Hannah, and (iv) an aggregate of 45,500 shares to six additional newly hired employees. The stock options will be issued under the Cortexyme, Inc. 2022 Inducement Plan with a grant date of May 23, 2022 and an exercise price equal to the closing price of a share of Cortexyme common stock on the grant date. The stock options are being issued as an inducement material to each new employee entering into employment with Cortexyme, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options vest over four years, with 25% vesting on the first anniversary of the vesting commencement date for each employee and the remainder vesting in 36 installments over the following three years, subject to each employee being continuously employed by Cortexyme as of such vesting dates. About Cortexyme Cortexyme, Inc. (Nasdaq: CRTX) is a clinical stage biopharmaceutical company dedicated to improving the lives of patients diagnosed with degenerative diseases. The company’s innovative pipeline includes a precision bone growth molecule and drug-targeting platform to treat rare skeletal diseases, bone cancer and injury, in addition to small molecule therapeutics targeting the infectious pathogen P. gingivalis’ role in degenerative disease progression, including for indications such as periodontal disease, oral potentially malignant disorders, and Alzheimer’s disease, among others.

Read More

MEDICAL

Dover To Acquire Manufacturer Of Flow-Measurement Devices For Biopharma And Semiconductor Production Applications

Dover | May 11, 2022

Dover (NYSE: DOV) announced today that it has entered into a definitive agreement to acquire Malema Engineering Corporation ("Malema"), a designer and manufacturer of high-precision, mission-critical flow-measurement and control instruments serving customers in the biopharmaceutical, semiconductor, and industrial sectors. Malema will become part of the PSG business unit within Dover's Pumps & Process Solutions segment. Malema's products will expand Dover's biopharma single-use production offering, which already includes Quattroflow pumps, CPC connectors, and em-tec flowmeters. Based in Boca Raton, FL, and with facilities in San Jose, CA, Singapore, South Korea, and India, Malema expects to generate approximately $40-45 million in revenue during the full year 2022 and has a robust growth outlook. Over the past four decades, Malema has cultivated a loyal base of blue-chip customers, OEMs, and end-users with substantial aftermarket and recurring revenue streams. Malema's first-of-its-kind single-use flow sensor using Coriolis technology offers superior flow-measurement performance and accuracy versus alternative technologies, reducing the potential for measurement error and eliminating the need for calibration in time-sensitive and contamination-intolerant environments. We see a tremendous long-term growth opportunity in the bioprocessing industry driven by a strong and growing pipeline of effective novel biologic drugs, biosimilars, protein therapies, non-COVID mRNA vaccines, as well as budding cell & gene therapies. Additionally, the growing adoption of more efficient single-use production processes supports a robust outlook for our offerings of single-use components to end-customers. We believe that pairing Malema's technology with our existing portfolio of single-use pumps for biopharma processing will greatly enhance the accuracy and value proposition of our solutions to our customers. PSG's President, Karl Buscher. We are methodically building out our biopharma platform through proactive capacity additions, new product development, and opportunistic acquisitions of highly-attractive niche component technologies, Malema represents a strategic and highly-complementary flow-control and sensing technology and further strengthens our sensor portfolio with new proprietary technology. In addition to attractive biopharma applications, we expect strong growth in the semiconductor space on the capacity expansion and re-shoring tailwinds." Richard J. Tobin, President and Chief Executive Officer of Dover. The purchase price is comprised of $225 million in cash at closing, subject to customary purchase price adjustments, and up to $50 million in contingent consideration dependent on the achievement of certain financial objectives over a two-year period. The transaction is expected to close in the second quarter and is subject to the satisfaction of customary closing conditions, including applicable regulatory approvals. About Dover: Dover is a diversified global manufacturer and solutions provider with annual revenue of approximately $8 billion. We deliver innovative equipment and components, consumable supplies, aftermarket parts, software and digital solutions, and support services through five operating segments: Engineered Products, Clean Energy & Fueling, Imaging & Identification, Pumps & Process Solutions, and Climate & Sustainability Technologies. Dover combines global scale with operational agility to lead the markets we serve. Recognized for our entrepreneurial approach for over 65 years, our team of over 25,000 employees takes an ownership mindset, collaborating with customers to redefine what's possible. Headquartered in Downers Grove, Illinois, Dover trades on the New York Stock Exchange under "DOV." About PSG: PSG is a global pump solution expert and leading manufacturer of pumps, systems, and related flow-control technology for the safe and efficient transfer of critical and valuable fluids and materials. Headquartered in Oakbrook Terrace, IL, PSG is comprised of several world-class brands, including Abaque®, All-Flo®, Almatec®, Blackmer®, Ebsray®, em-tec®, Griswold®, Hydro Systems™, Mouvex®, Neptune™, Quantex™, Quattroflow®, and Wilden®. PSG products are manufactured in three continents – North America, Europe, and Asia – in state-of-the-art facilities that practice lean manufacturing and are ISO-certified. PSG is part of the Pumps & Process Solutions segment of Dover Corporation.

Read More

Spotlight

Tuberculosis (TB) is currently a global pandemic. The World Health Organization (WHO) estimates that 2 billion people (a third of the worlds population) is infected with Mycobacterium tuberculosis, the bacterium which causes the disease. Fisher BioServices UK is currently collaborating with partners on a global phase III clinical trial to create a biobank of blood, urine and sputum samples taken from TB-positive patients during treatment.

Resources